Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia

This study is testing whether a combination of two treatments — an NMDA receptor enhancer (which targets brain chemistry believed to be abnormal in schizophrenia) and an antioxidant — can reduce symptoms of schizophrenia when added to existing antipsychotic medication. The goal is to address aspects of schizophrenia, including thinking problems, that antipsychotics alone do not fully control. **You may be eligible if...** - You have a confirmed diagnosis of schizophrenia (based on DSM-5 criteria) - You remain symptomatic despite being on a stable antipsychotic dose for at least 3 months - Your overall symptom burden is significant (total PANSS score of 60 or above) - You are willing to participate and provide informed consent **You may NOT be eligible if...** - You have an intellectual disability or active substance/alcohol use disorder - You have a history of epilepsy, head trauma, stroke, or another serious brain or nervous system condition - Your lab tests show significant abnormalities - You are pregnant or breastfeeding - You are unable to follow the study protocol Talk to your doctor to see if this trial is right for you.